A new drug-eluting stent that does not live up to its promise

David R. Holmes

doi:10.1038/nrcardio.2009.117

A new drug-eluting stent that does not live up to its promise

David R. Holmes

Cardiovascular Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Drug-eluting stents are an established treatment option for coronary artery disease, although they are not without their problems. The MAHOROBA® stent attempts to harness the theoretical advantages of both tacrolimus and polymer degradation, but has proved not to be effective in the treatment of de novo coronary lesions.

Original language	English (US)
Pages (from-to)	500-501
Number of pages	2
Journal	Nature Reviews Cardiology
Volume	6
Issue number	8
DOIs	https://doi.org/10.1038/nrcardio.2009.117
State	Published - Aug 2009

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1038/nrcardio.2009.117

Cite this

@article{ff25eed121454d3c876a5e6d82eb279b,

title = "A new drug-eluting stent that does not live up to its promise",

abstract = "Drug-eluting stents are an established treatment option for coronary artery disease, although they are not without their problems. The MAHOROBA{\textregistered} stent attempts to harness the theoretical advantages of both tacrolimus and polymer degradation, but has proved not to be effective in the treatment of de novo coronary lesions.",

author = "Holmes, {David R.}",

year = "2009",

month = aug,

doi = "10.1038/nrcardio.2009.117",

language = "English (US)",

volume = "6",

pages = "500--501",

journal = "Nature Reviews Cardiology",

issn = "1759-5002",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - A new drug-eluting stent that does not live up to its promise

AU - Holmes, David R.

PY - 2009/8

Y1 - 2009/8

N2 - Drug-eluting stents are an established treatment option for coronary artery disease, although they are not without their problems. The MAHOROBA® stent attempts to harness the theoretical advantages of both tacrolimus and polymer degradation, but has proved not to be effective in the treatment of de novo coronary lesions.

AB - Drug-eluting stents are an established treatment option for coronary artery disease, although they are not without their problems. The MAHOROBA® stent attempts to harness the theoretical advantages of both tacrolimus and polymer degradation, but has proved not to be effective in the treatment of de novo coronary lesions.

UR - http://www.scopus.com/inward/record.url?scp=70350445235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350445235&partnerID=8YFLogxK

U2 - 10.1038/nrcardio.2009.117

DO - 10.1038/nrcardio.2009.117

M3 - Article

C2 - 19633676

AN - SCOPUS:70350445235

SN - 1759-5002

VL - 6

SP - 500

EP - 501

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

IS - 8

ER -

A new drug-eluting stent that does not live up to its promise

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this